Searchable abstracts of presentations at key conferences in endocrinology

ea0099p521 | Pituitary and Neuroendocrinology | ECE2024

Assessing long-term safety and efficacy of osilodrostat in prior- and new-use patients with endogenous cushing’s syndrome: a 1-year real-world interim analysis of the non-interventional, multinational LINC 6 study

Castinetti Frederic , Geer Eliza , Biller Beverly , Feelders Richard , Fleseriu Maria , Pivonello Rosario , Reincke Martin , Tabarin Antoine , Le Mouhaer Jeannie , Stermenska Julia , Maldonado Mario , Bancos Irina

Introduction: Potent 11β-hydroxylase inhibitor osilodrostat provides cortisol level control in patients with Cushing’s syndrome (CS), as demonstrated by the LINC clinical development programme in Cushing’s disease (CD) patients.1 We report data from year 1 of the prospective observational LINC6 study (NCT05382156), evaluating long-term safety and efficacy of osilodrostat in CS patients during 3 years of routine clinical practice.<p class="abstext"...